Limited options for treating moderate-severe pain led to an overreliance on opioids and the current opioid epidemic. Addressing the factors contributing to a dearth of effective alternatives and re-energizing the development of pain therapeutics is necessary to quell this epidemic.
At Face Value, the Opioid Epidemic Has Created an Environment Conducive to Developing Novel Pain Therapeutics Opioids are currently the most widely prescribed class of drugs in the United States, with 245 million prescriptions dispensed in 2014 (Volkow and McLellan, 2016) . These powerful analgesics are also highly rewarding, resulting in the diversion and misuse that fuels what is now referred to as the ''opioid epidemic'' (Volkow and McLellan, 2016) . The magnitude of this epidemic is startling: it is estimated that more than 10 million Americans (or >4% of the adult population) currently misuse prescription opioids. The most visible manifestations of this epidemic are the estimated 19,000 overdose deaths reported in 2014 (Compton et al., 2016) and 750,000 emergency department visits linked to opiate misuse. The misuse of prescription opioids has also resulted in a resurgence of heroin abuse because it, together with illicit fentanyl and its analogs, offer less expensive and more accessible alternatives. This has resulted in a dramatic rise in the number of fatalities attributed to heroin (and heroin adulterated with fentanyl), with over 10,000 deaths reported in 2014 (Compton et al., 2016) . Among the less publicized but nonetheless consequential aspects of this epidemic are a large increase in the number of infants born with neonatal abstinence syndrome, whose incidence has increased almost 3-fold between 2000 and 2009 and the spread of hepatitis C and HIV that can be traced to injection drug use, much of it illicit opioids.
Even in the absence of an opioid epidemic, at face value, there is a market opportunity to develop novel pain therapeutics. Thus, more than 125 million adults in the United States suffer from either acute or chronic pain. An obvious need for improved treatments, especially in chronic pain conditions, appears to create an ideal environment to foster the development of novel pain therapies. Nonetheless, efforts in this direction have lagged far behind the need. Here we discuss some of the factors contributing to this paradox.
Industry's Retreat from Neuroscience Research and Development Intersects the Opioid Epidemic
Over the past decade, the pharmaceutical sector has dramatically reduced investment in neuroscience research and development (Miller, 2010) , a period coinciding with the dramatic rise in opioid misuse. Pain programs, with more than 150 drug candidates in various stages of development in 2008 (Miller, 2010) , were affected by this contraction. While there are multiple factors contributing to the retreat from neuroscience drug development, Andrew Witty, the CEO of GlaxoSmithKline, explained the termination of neuroscience (including pain) programs as areas where '' . the probability of success is relatively low . and the cost of attaining success is disproportionately high'' (Miller, 2010) . This has resulted in the redeployment of capital (both real and human) to therapeutic areas viewed as having a higher probability of technical success. These areas are advantaged by tools often absent in the development of pain therapeutics such as animal models with high predictive validity, the ability to measure target engagement (to facilitate dose selection), and biomarkers that can be used for diagnosis, patient stratification, and monitoring both disease progression and drug efficacy (Box 1).
Low Hanging Fruit Is Harvested First
The drug development cycle for a new chemical entity requires more than 15 years and a capitalized expenditure approaching $2 billion (Paul et al., 2010) . While both time and cost estimates vary across therapeutic areas, drug development in neuroscience is generally ranked as most risky based on development time, cost, and clinical approval success rate (Miller, 2010) . Thus, it is not surprising that the most immediate response to the opioid epidemic has been the reformulation of already approved opioids, incorporating abuse deterrent features: clearly a strategy of harvesting low hanging fruit from a development perspective. First introduced in 2010, these products deter misuse by injection and inhalation through physical modification of the formulation (e.g., forming a viscous gel when crushed) or by incorporating a sequestered opioid antagonist that is released when tampering occurs. Injection and insufflation are the favored routes of administration for abuse since they result in rapid delivery of the drug into the brain, which maximizes their rewarding effects (Volkow and McLellan, 2016) . However, currently approved products do not prevent misuse of multiple doses taken by the intended (oral) route. Second-generation products in development employ more sophisticated technologies such as chemical modification of opioids that either have slow entry into the CNS or that require enzymatic digestion to release an active opioid. Such products, when approved, will deter misuse by injection and inhalation and make misuse by the oral route less attractive. However, abuse deterrent formulations are currently ''branded,'' and more costly than generic opioids, limiting their use to insurance providers willing to cover the higher costs of these formulations.
The ''Better than the Beatles'' Phenomenon, at Least for Acute Pain Opioids are very effective for treating moderate to severe acute pain originating from multiple sources such as trauma (e.g., burns, broken bones) and surgery. The combination of a medication (or in this instance, a class of medications) with high efficacy and relatively low cost has been termed the ''better than the Beatles'' phenomenon (Scannell et al., 2012) and presents a strong disincentive to develop alternatives for the treatment of acute pain.
In contrast, evidence for the effectiveness of opioids in treating non-cancer chronic pain is less compelling (Volkow and McLellan, 2016) . Opioids have inherent limitations when used for the management of chronic pain, most notably the development of tolerance to the analgesic effects and the emergence of physical dependence, both phenomena strongly associated with chronic use (Volkow and McLellan, 2016) . Nonetheless, opioids are recommended in clinical practice guidelines for the management of non-cancer chronic pain in selected patients, albeit with the caveat that there are insufficient data to guide appropriate patient assessment, selection of the type of opioid, and dosing strategy. There are multiple options available for treating chronic pain conditions, including cyclooxygenase inhibitors (ibuprofen, celecoxib), amine uptake inhibitors (amitryptylline, duloxetine, milnacipran), and modulators of voltagedependent calcium channels (e.g., pregabalin, gabapentin). Many of these alternatives are generic, but for chronic pain conditions, the ''better than the Beatles'' principle does not obtain because of low efficacy. This is exemplified in a recent meta-analysis of 229 studies treating various neuropathic pain conditions (such as post-herpetic neuralgia, painful polyneuropathy, and peripheral nerve injury) that recommended uptake inhibitors and calcium channel blockers as first-line treatments with a ''strong'' endorsement for use. This recommendation is based on number needed to treat (NNT) values between 6 and 7, using endpoints such as either a 30%-50% reduction in pain scores or moderate pain relief. NNT values in this range suggest that for every patient achieving this moderate degree of pain relief, five to six would receive less (or no) benefit. While these alternatives all carry safety and tolerability concerns, opioids are given a ''weak'' recommendation for use and assigned as third line therapy based primarily on concerns centered on abuse (Finnerup et al., 2015) . Such concerns are not misplaced: there is compelling evidence (Edlund et al., 2014) that the incidence of opioid use disorders (OUDs) is dramatically increased by chronic use. In a cohort of more than 500,000 patients with a new diagnosis of chronic non-cancer pain (and no opioid use in the prior 6 months), the odds ratio (OR) for developing an OUD was 14.9 for patients on chronic (defined here as >3 months of use) low doses of opioids and 122.5 for patients on high doses of opioids (compared to subjects not receiving opioids), respectively. The low efficacy of non-opioid alternatives also pertains in other chronic pain conditions. For example, in fibromyalgia, a disorder characterized by widespread musculoskeletal pain affecting more than 5 million patients in the U.S., a meta-analysis with a cohort of more than 4,000 patients found that milnacipran resulted in an NNT of 8 to produce a moderate (30%) reduction in pain relief (Derry et al., 2012) . Pregabalin, also FDA approved to treat fibromyalgia, is no more effective: in a 14 week study with a 30% reduction in pain relief as the primary outcome measure, NNT values ranged from 6 to 9 (Arnold et al., 2008) . These data demonstrate both a compelling need and a market opportunity to develop more effective treatments for chronic pain Novel Pain Therapeutics: Quo Vadis? Because of both the time required to develop a medication and the widespread retreat of the pharmaceutical sector from neuroscience research, it would be unrealistic to expect that novel pain therapeutics will emerge as an immediate response to the opioid epidemic. Furthermore, the reallocation of resources within the pharmaceutical sector also leaves a ''development void'' for novel pain targets identified by academia and small biotechnology companies who traditionally look to partners with both the expertise and capital to translate these discoveries into products.
Despite a dramatic reduction in the number of pain programs, there are a scattering of projects, mostly clinical, that remain in development. If one or more of these projects results in a product approval, even a modest commercial success could reinvigorate pain research and development. Nonetheless, moving forward, the development strategy for pain therapeutics must change: rather than hunting drug targets for treating all types of chronic pain, bespoke therapeutics will be developed based on better understanding the pathophysiology of pain. One notable success using this strategy is the biologic, etanercept (Enbrel), a tumor necrosis factor (TNF) inhibitor that acts as a disease-modifying agent in rheumatoid arthritis. Another biologic, tanezumab, a monoclonal antibody to nerve growth factor (NGF), appears to be effective as monotherapy in osteoarthritis (Schnitzer et al., 2015) . NGF elevations are manifested in other painful conditions (such as chronic headaches and cystitis), suggesting this mechanism may be more broadly applicable. However, to put this in perspective, the development of tanezumab was grounded on findings of elevated NGF levels in the synovial fluid of arthritic patients reported more than 25 years ago.
Validating the strategy of developing therapeutics based on a better understanding of the biological processes associated with pain comes from a very rare form of inherited erythromelalgia (IEM). Gain-of-function mutations in the SCN9A gene encoding the Nav1.7 subtype of sodium channel are responsible for this chronic pain condition, producing burning pain sensations in the extremities that can be triggered by mild heat or increase in body temperature. A small molecule Nav 1.7 antagonist (PF 05089771) reduced heat-induced pain in a very small group of IEM patients (Cao et al., 2016) . Perhaps more important, sensory neurons derived from iPSC cell lines from these patients mimicked the hyperexcitability and aberrant responses to heat seen in the clinic. Such findings portend a means of patient stratification or selection in other chronic pain conditions. From the listing of trials in http://www. clinicaltrials.gov, it is unclear whether this compound will move forward in development. However, at least one other Nav1.7 blocker, raxatrigine (licensed from GlaxoSmithKline in 2010 to Convergence Pharmaceuticals), remains in clinical development. Based on reports of efficacy in trigeminal neuralgia, the sponsor is preparing a Phase III study and has several Nav1.7 antagonists in various stages of development.
Moving forward, advances in structural biology and computational chemistry will enable a rapid identification of lead compounds through the in silico interrogation of putative pain targets. The introduction of transformative technologies such as iPSCs and CRISPR can facilitate hypothesis testing, from yielding new animal models with improved translational fidelity to guiding patient selection and stratification. Expanding the use of imaging technologies, both as a means for assessing target engagement and as potential biomarkers for assessing pain, will provide powerful tools that can also facilitate the development of new pain therapeutics. An increased use of pharmacogenomics as a means to identity patients who are more likely to respond to a particular therapeutic intervention will increase the probability of executing a successful clinical trial. These innovations, coupled with improvements in the conduct and execution of clinical trials, including more sensitive pain measurements and the ability to recruit the ''right'' patient population may ultimately re-incentivize private sector investment.
Concluding Remarks
Policy changes, such as those recommended in the National Pain Strategy, the expansion and improvement of prescription drug monitoring programs, and updated CDC pain guidelines that inform prescribers on best practices for using opioids in non-cancer chronic pain, will help prevent the diversion of opioid medications and contain the opioid epidemic. But, in addition, given the burden of chronic pain conditions on our society and its devastating consequences to the individual, there is an equally urgent need and economic imperative to develop novel therapeutics.
Pain is currently the most prevalent, disabling, and costly health problem in the United States and will certainly continue to grow as our population ages. The societal costs of pain exceed the annual combined costs of heart disease, diabetes, and cancer, yet basic, clinical, and translational research on pain represented less than 3% of the NIH budget between 2012 and 2015, with no increases projected at least through 2017. Expanding investment in pain research is key to accelerating the development of innovative pain therapeutics. Additional structural changes, ranging from private public partnerships aimed at expediting the development of improved pain therapeutics to economic incentives (e.g., patent term extension) for developing truly innovative pain therapeutics may, in the long term, be the most effective means of accelerating the development of safer and more effective analgesics.
Moreover, simultaneously addressing the ''pain epidemic'' and the need for newer, more effective pain therapies is a critical component of a comprehensive approach for solving the current opioid epidemic as well as preventing a similar crisis in the future.
